FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC
Telemedicine Consult - Dr. Gish
Schedule Telemedicine Consult with Dr. Gish

FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC

FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC

The FDA has approved the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.1Additionally, the responses were observed across patient subgroups defined by etiology, geography, baseline alpha fetoprotein levels, and extrahepatic spread. The 65% ORR comprised a 4% (n = 1) complete response rate and a 61% (n = 14) partial response rate. Additionally, 7 (30%) patients had stable disease and 1 (4%) patient had progressive disease. A disease control rate of ≥6 months was reported for 16 (70%) patients.

Read Article


Metadata